Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 84 articles:
HTML format



Single Articles


    February 2024
  1. VELLKY JE, Kirkpatrick BJ, Gutgesell LC, Morales M, et al
    ERBB3 overexpression is enriched in diverse patient populations with castration-sensitive prostate cancer and is associated with a unique AR activity signature.
    Clin Cancer Res. 2024 Feb 2. doi: 10.1158/1078-0432.CCR-23-2161.
    PubMed     Abstract available


  2. DORFF T, Horvath LG, Autio K, Bernard-Tessier A, et al
    A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2024 Feb 1. doi: 10.1158/1078-0432.CCR-23-2978.
    PubMed     Abstract available


    January 2024
  3. HALABI S, Guo S, Park JJ, Nanus DM, et al
    The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Clin Cancer Res. 2024 Jan 18. doi: 10.1158/1078-0432.CCR-23-3017.
    PubMed     Abstract available


  4. ABIDA W, Hahn AW, Shore N, Agarwal N, et al
    Phase 1 Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer Progressing on Enzalutamide.
    Clin Cancer Res. 2024 Jan 16. doi: 10.1158/1078-0432.CCR-23-3508.
    PubMed     Abstract available


    September 2023
  5. CHAUDAGAR K, Hieromnimon HM, Kelley A, Labadie B, et al
    Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis.
    Clin Cancer Res. 2023 Sep 18. doi: 10.1158/1078-0432.CCR-23-1441.
    PubMed     Abstract available


    August 2023
  6. GENG C, Zhang MC, Manyam GC, Vykoukal JV, et al
    SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor-induced growth suppression.
    Clin Cancer Res. 2023 Aug 15:CCR-23-1439. doi: 10.1158/1078-0432.CCR-23-1439.
    PubMed     Abstract available


    July 2023
  7. CHEHRAZI-RAFFLE A, Tukachinsky H, Toye E, Sivakumar S, et al
    Unique spectrum of activating BRAF alterations in prostate cancer.
    Clin Cancer Res. 2023 Jul 21:CCR-23-1393. doi: 10.1158/1078-0432.CCR-23-1393.
    PubMed     Abstract available


  8. HWANG J, Shi X, Elliott A, Arnoff TE, et al
    Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes.
    Clin Cancer Res. 2023;29:2702-2713.
    PubMed     Abstract available


  9. FLESHNER NE, Sayyid RK, Hansen AR, Chin JLK, et al
    Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial.
    Clin Cancer Res. 2023 Jul 13:CCR-23-0731. doi: 10.1158/1078-0432.CCR-23-0731.
    PubMed     Abstract available


    June 2023
  10. MENSSOURI N, Poiraudeau L, Helissey C, Bigot L, et al
    Genomic profiling of metastatic castration-resistant prostate cancer samples resistant to androgen-receptor pathway inhibitors.
    Clin Cancer Res. 2023 Jun 26:CCR-22-3736. doi: 10.1158/1078-0432.CCR-22-3736.
    PubMed     Abstract available


  11. POOK D, Geynisman DM, Carles J, de Braud F, et al
    A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2023 Jun 20:CCR-22-2585. doi: 10.1158/1078-0432.CCR-22-2585.
    PubMed     Abstract available


  12. SARTOR O
    Circulating Tumor DNA Biomarkers for Response Assessment in Prostate Cancer.
    Clin Cancer Res. 2023 Jun 2:OF1-OF3. doi: 10.1158/1078-0432.CCR-23-1043.
    PubMed     Abstract available


    May 2023
  13. SARTOR O
    Circulating tumor DNA biomarkers for response assessment in prostate cancer.
    Clin Cancer Res. 2023 May 25:CCR-23-1043. doi: 10.1158/1078-0432.CCR-23-1043.
    PubMed     Abstract available


  14. BHINDER B, Ferguson A, Sigouros M, Uppal M, et al
    The Immunogenomic Landscape of Neuroendocrine Prostate Cancer.
    Clin Cancer Res. 2023 May 24:CCR-22-3743. doi: 10.1158/1078-0432.CCR-22-3743.
    PubMed     Abstract available


    April 2023
  15. ANTONARAKIS ES, Subudhi SK, Pieczonka CM, Karsh LI, et al
    Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials.
    Clin Cancer Res. 2023 Apr 14:CCR-22-3832. doi: 10.1158/1078-0432.CCR-22-3832.
    PubMed     Abstract available


    March 2023
  16. TOLMEIJER SH, Boerrigter E, Sumiyoshi T, Kwan EM, et al
    Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2023 Mar 30:CCR-22-2998. doi: 10.1158/1078-0432.CCR-22-2998.
    PubMed     Abstract available


  17. SPERGER JM, Helzer KT, Stahlfeld CN, Jiang D, et al
    Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer.
    Clin Cancer Res. 2023 Mar 20:CCR-22-1305. doi: 10.1158/1078-0432.CCR-22-1305.
    PubMed     Abstract available


  18. BIDKAR AP, Wang S, Bobba KN, Chan E, et al
    Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy.
    Clin Cancer Res. 2023 Mar 14:CCR-22-3291. doi: 10.1158/1078-0432.CCR-22-3291.
    PubMed     Abstract available


  19. OMLIN A, Cathomas R, von Amsberg G, Reuter C, et al
    Randomized phase 2 Cabazitaxel dose individualization and Neutropenia prevention Trial (CAINTA) in patients with metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2023 Mar 14:CCR-22-3360. doi: 10.1158/1078-0432.CCR-22-3360.
    PubMed     Abstract available


  20. GUPTA S, Halabi S, Yang Q, Roy A, et al
    PSMA-positive circulating tumor cell detection and outcomes with abiraterone or enzalutamide treatment in men with metastatic castrate resistant prostate cancer.
    Clin Cancer Res. 2023 Mar 10:CCR-22-3233. doi: 10.1158/1078-0432.CCR-22-3233.
    PubMed     Abstract available


  21. CHAUDAGAR K, Hieromnimon HM, Khurana R, Labadie B, et al
    Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer.
    Clin Cancer Res. 2023 Mar 2:CCR-22-3350. doi: 10.1158/1078-0432.CCR-22-3350.
    PubMed     Abstract available


  22. ROBERT C, Lebbe C, Lesimple T, Lundstrom E, et al
    Phase I Study of Androgen Deprivation Therapy in Combination with Anti-PD-1 in Melanoma Patients Pretreated with Anti-PD-1.
    Clin Cancer Res. 2023;29:858-865.
    PubMed     Abstract available


  23. CHEEMA AK, Li Y, Ventimiglia M, Kowalczyk K, et al
    Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers.
    Clin Cancer Res. 2023;29:921-929.
    PubMed     Abstract available


    December 2022
  24. FALLAH J, Agrawal S, Gittleman H, Fiero MH, et al
    FDA Approval Summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2022 Dec 5:CCR-22-2875. doi: 10.1158/1078-0432.CCR-22-2875.
    PubMed     Abstract available


    November 2022
  25. LIM EA, Bendell JC, Falchook GS, Bauer TM, et al
    Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
    Clin Cancer Res. 2022;28:4871-4884.
    PubMed     Abstract available


  26. QUINN Z, Leiby B, Sonpavde G, Choudhury AD, et al
    Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate Resistant Prostate Cancer.
    Clin Cancer Res. 2022 Nov 2. pii: 710187. doi: 10.1158/1078-0432.CCR-22-2526.
    PubMed     Abstract available


  27. MATSUBARA N, de Bono J, Olmos D, Procopio G, et al
    Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2 or ATM Alterations Identified by Testing Circulating Tumor DNA.
    Clin Cancer Res. 2022 Nov 1. pii: 710156. doi: 10.1158/1078-0432.CCR-21-3577.
    PubMed     Abstract available


    October 2022
  28. FENG E, Rydzewski NR, Zhang M, Lundberg A, et al
    Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2022 Oct 19. pii: 709863. doi: 10.1158/1078-0432.CCR-22-2567.
    PubMed     Abstract available


  29. VAISHAMPAYAN UN, Thakur A, Chen W, Deol A, et al
    Phase II trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer.
    Clin Cancer Res. 2022 Oct 18. pii: 709809. doi: 10.1158/1078-0432.CCR-22-1601.
    PubMed     Abstract available


  30. FENDLER WP, Pabst KM, Kessler L, Fragoso Costa P, et al
    Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities.
    Clin Cancer Res. 2022;28:4346-4353.
    PubMed     Abstract available


    September 2022
  31. PLYM A, Zhang Y, Stopsack KH, Jee YH, et al
    Family history of prostate and breast cancer integrated with a polygenic risk score identifies men at highest risk of dying from prostate cancer before age 75 years.
    Clin Cancer Res. 2022 Sep 14. pii: 709205. doi: 10.1158/1078-0432.CCR-22-1723.
    PubMed     Abstract available


  32. SWAMI U, Graf RP, Nussenzveig RH, Fisher V, et al
    SPOP mutations as a Predictive Biomarker for Androgen Receptor-Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.
    Clin Cancer Res. 2022 Sep 11. pii: 709162. doi: 10.1158/1078-0432.CCR-22-2228.
    PubMed     Abstract available


    August 2022
  33. CHI KN, Barnicle A, Sibilla C, Lai Z, et al
    Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound.
    Clin Cancer Res. 2022 Aug 31:OF1-OF11. doi: 10.1158/1078-0432.CCR-22-0931.
    PubMed     Abstract available


    July 2022
  34. NGUYEN DT, Yang W, Renganathan A, Weimholt C, et al
    Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2022 Jul 18. pii: 707054. doi: 10.1158/1078-0432.CCR-21-3603.
    PubMed     Abstract available


  35. AGGARWAL R, Starodub AN, Koh BD, Xing G, et al
    Phase 1b Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2022 Jul 11. pii: 706956. doi: 10.1158/1078-0432.CCR-22-0175.
    PubMed     Abstract available


  36. FISHER NC, Byrne RM, Leslie H, Wood C, et al
    Biological misinterpretation of transcriptional signatures in tumour samples can unknowingly undermine mechanistic understanding and faithful alignment with preclinical data.
    Clin Cancer Res. 2022 Jul 6. pii: 706888. doi: 10.1158/1078-0432.CCR-22-1102.
    PubMed     Abstract available


  37. WANG T, Song W, Chen Y, Chen R, et al
    Correction: Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling.
    Clin Cancer Res. 2022;28:2970.
    PubMed    


    June 2022
  38. SOWALSKY AG, Figueiredo I, Lis RT, Coleman I, et al
    Assessment of Androgen Receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancer.
    Clin Cancer Res. 2022 Jun 13. pii: 704873. doi: 10.1158/1078-0432.CCR-22-0851.
    PubMed     Abstract available


  39. CHAKRABORTY G, Nandakumar S, Hirani R, Nguyen B, et al
    The impact of PIK3R1 mutations and insulin-PI3K-glycolytic pathway regulation in prostate cancer.
    Clin Cancer Res. 2022 Jun 7. pii: 699404. doi: 10.1158/1078-0432.CCR-21-4272.
    PubMed     Abstract available


  40. CHOUDHURY AD, Higano CS, de Bono JS, Cook N, et al
    A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kbeta/delta, in Patients with Advanced Solid Tumors.
    Clin Cancer Res. 2022;28:2257-2269.
    PubMed     Abstract available


    May 2022
  41. ZHAO N, Chopra S, Trepka K, Wang YH, et al
    CUB domain containing protein 1 (CDCP1) is a target for radioligand therapy in castration resistant prostate cancer including PSMA null disease.
    Clin Cancer Res. 2022 May 23. pii: 699115. doi: 10.1158/1078-0432.CCR-21-3858.
    PubMed     Abstract available


  42. COLEMAN IM, DeSarkar N, Morrissey C, Xin L, et al
    Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2022 May 12. pii: 698880. doi: 10.1158/1078-0432.CCR-21-4289.
    PubMed     Abstract available


  43. SHEEHAN B, Neeb A, Buroni L, Paschalis A, et al
    Prostate Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer.
    Clin Cancer Res. 2022 May 12. pii: 698876. doi: 10.1158/1078-0432.CCR-21-4531.
    PubMed     Abstract available


    April 2022
  44. MARKOWSKI MC, Tutrone R, Pieczonka C, Barnette KG, et al
    A Phase 1b/2 Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men With Metastatic Castration-Resistant Prostate Cancer with Progression on an Androgen Receptor Targeting Agent.
    Clin Cancer Res. 2022 Apr 13. pii: 694403. doi: 10.1158/1078-0432.CCR-22-0162.
    PubMed     Abstract available


  45. SWEENEY CJ, Percent IJ, Babu S, Cultrera JL, et al
    Phase 1b/2 Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2022 Apr 1. pii: 694115. doi: 10.1158/1078-0432.CCR-21-2326.
    PubMed     Abstract available


  46. WESTPHALEN CB, Fine AD, Andre F, Ganesan S, et al
    Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score.
    Clin Cancer Res. 2022;28:1412-1421.
    PubMed     Abstract available


    February 2022
  47. DE KOUCHKOVSKY I, Rao A, Carneiro BA, Zhang L, et al
    A phase Ib/II study of the CDK 4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2022 Feb 17. pii: 681559. doi: 10.1158/1078-0432.CCR-21-4302.
    PubMed     Abstract available


  48. SERRITELLA AV, Shevrin D, Heath EI, Wade JL, et al
    Phase I/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2022 Feb 2. pii: 1078-0432.CCR-21-4049.
    PubMed     Abstract available


    January 2022
  49. HUSSAIN M, Corcoran C, Sibilla C, Fizazi K, et al
    Tumor Genomic Testing for >4000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).
    Clin Cancer Res. 2022 Jan 28. pii: 1078-0432.CCR-21-3940.
    PubMed     Abstract available


  50. DYLGJERI E, Kothari V, Shafi AA, Semenova G, et al
    A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2022 Jan 25. pii: 1078-0432.CCR-21-1846.
    PubMed     Abstract available


    December 2021
  51. ZHAO JL, Fizazi K, Saad F, Chi KN, et al
    The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial.
    Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-1090.
    PubMed     Abstract available


  52. BERCHUCK JE, Baca SC, McClure HM, Korthauer K, et al
    Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis.
    Clin Cancer Res. 2021 Dec 14. pii: 1078-0432.CCR-21-3762.
    PubMed     Abstract available


    November 2021
  53. PENG S, Hu P, Xiao YT, Lu W, et al
    Single-cell analysis reveals EP4 as a target for restoring T cell infiltration and sensitizing prostate cancer to immunotherapy.
    Clin Cancer Res. 2021 Nov 5. pii: 1078-0432.CCR-21-0299.
    PubMed     Abstract available


  54. AL-UBAIDI FLT, Schultz N, Loseva O, Egevad L, et al
    Editor's Note: Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer.
    Clin Cancer Res. 2021;27:6066.
    PubMed    


    October 2021
  55. DORFF TB, Narayan V, Forman SJ, Zang PD, et al
    Novel Redirected T Cell Immunotherapies for Advanced Prostate Cancer.
    Clin Cancer Res. 2021 Oct 21. pii: 1078-0432.CCR-21-1483.
    PubMed     Abstract available


  56. STOPSACK KH, Nandakumar S, Arora K, Nguyen B, et al
    Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors.
    Clin Cancer Res. 2021 Oct 19. pii: 1078-0432.CCR-21-2577.
    PubMed     Abstract available


  57. LOEHR A, Patnaik A, Campbell D, Shapiro J, et al
    Response to rucaparib in BRCA-mutant metastatic castration-resistant prostate cancer identified by genomic testing in the TRITON2 study.
    Clin Cancer Res. 2021 Oct 1. pii: 1078-0432.CCR-21-2199.
    PubMed     Abstract available


    September 2021
  58. ZHANG H, Orme JJ, Abraha F, Stish BJ, et al
    Phase II evaluation of Stereotactic Ablative Radiotherapy (SABR) and immunity in (11)C-Choline-PET/CT-identified oligometastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-2510.
    PubMed     Abstract available


  59. MIZUNO K, Sumiyoshi T, Okegawa T, Terada N, et al
    Clinical impact of detecting low-frequency variants in cell-free DNA on treatment of castration-resistant prostate cancer.
    Clin Cancer Res. 2021 Sep 15. pii: 1078-0432.CCR-21-2328.
    PubMed     Abstract available


  60. JEONG IG, Lim B, Yun SC, Lim JH, et al
    Adjuvant Low-dose Statin Use after Radical Prostatectomy: The PRO-STAT Randomized Clinical Trial.
    Clin Cancer Res. 2021;27:5004-5011.
    PubMed     Abstract available


    August 2021
  61. MOSTAGHEL EA, Marck BT, Kolokythas O, Chew F, et al
    Circulating and intra-tumoral adrenal androgens correlate with response to abiraterone in men with castration resistant prostate cancer.
    Clin Cancer Res. 2021 Aug 18. pii: 1078-0432.CCR-21-1819.
    PubMed     Abstract available


    July 2021
  62. MURTOLA TJ, Siltari A
    Statins for prostate cancer: when and how much?
    Clin Cancer Res. 2021 Jul 19. pii: 1078-0432.CCR-21-1891.
    PubMed     Abstract available


  63. SARKER D, Dawson NA, Aparicio AM, Dorff TB, et al
    A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kbeta inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2021 Jul 19. pii: 1078-0432.CCR-21-1115.
    PubMed     Abstract available


  64. BROWN LC, Halabi S, Schonhoft JD, Yang Q, et al
    Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.
    Clin Cancer Res. 2021;27:4077-4088.
    PubMed     Abstract available


  65. DE BONO JS, Fleming MT, Wang JS, Cathomas R, et al
    Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide.
    Clin Cancer Res. 2021;27:3602-3609.
    PubMed     Abstract available


    June 2021
  66. TURNER PG, Jain S, Cole A, Grey A, et al
    Toxicity and efficacy of concurrent androgen deprivation therapy, pelvic radiotherapy, and radium-223 in patients with de-novo metastatic hormone sensitive prostate cancer.
    Clin Cancer Res. 2021 Jun 29. pii: 1078-0432.CCR-21-0685.
    PubMed     Abstract available


  67. CALAGUA C, Ficial M, Jansen CS, Hirz T, et al
    A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.
    Clin Cancer Res. 2021 Jun 24. pii: 1078-0432.CCR-21-0121.
    PubMed     Abstract available


  68. TANG Z, Pilie PG, Geng C, Manyam GC, et al
    ATR inhibitor-induced CDK1-SPOP axis destabilizes PD-L1 and enhances cytotoxicity in prostate cancer.
    Clin Cancer Res. 2021 Jun 24. pii: 1078-0432.CCR-21-1010.
    PubMed     Abstract available


  69. KIM DH, Sun D, Storck WK, Welker Leng KR, et al
    BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.
    Clin Cancer Res. 2021 Jun 18. pii: 1078-0432.CCR-20-4968.
    PubMed     Abstract available


  70. SMITH MR, Thomas S, Gormley M, Chowdhury S, et al
    Blood Biomarker Landscape in Patients with High-Risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease.
    Clin Cancer Res. 2021 Jun 10. pii: 1078-0432.CCR-21-0358.
    PubMed     Abstract available


  71. FONG L, Morris MJ, Sartor O, Higano CS, et al
    A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2021 Jun 9. pii: 1078-0432.CCR-21-0063.
    PubMed     Abstract available


  72. ANNALA M, Taavitsainen S, Khalaf DJ, Vandekerkhove G, et al
    Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition.
    Clin Cancer Res. 2021 Jun 3. pii: 1078-0432.CCR-21-1625.
    PubMed     Abstract available


  73. HAWKEY NM, Armstrong AJ
    Liquid Biopsy: It's the Bloody Truth!
    Clin Cancer Res. 2021;27:2961-2963.
    PubMed     Abstract available


  74. HEGDE A, Jayaprakash P, Couillault CA, Piha-Paul S, et al
    A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies.
    Clin Cancer Res. 2021;27:3050-3060.
    PubMed     Abstract available


    May 2021
  75. HAMMER S, Schlicker A, Zitzmann-Kolbe S, Baumgart S, et al
    Darolutamide potentiates the antitumor efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC) by a dual mode-of-action in prostate cancer models.
    Clin Cancer Res. 2021 May 25. pii: 1078-0432.CCR-21-0342.
    PubMed     Abstract available


  76. MUNN LL, Stylianopoulos T, Jain NK, Hardin CC, et al
    Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer.
    Clin Cancer Res. 2021;27:2706-2711.
    PubMed     Abstract available


  77. KAWAMOTO K, Okino ST, Place RF, Urakami S, et al
    Editor's Note: Epigenetic Modifications of RASSF1A Gene through Chromatin Remodeling in Prostate Cancer.
    Clin Cancer Res. 2021;27:2665.
    PubMed    


    April 2021
  78. TRUE LD, Chen DL
    How accurately does PSMA inhibitor 18F-DCFPyL-PET-CT image prostate cancer?
    Clin Cancer Res. 2021 Apr 23. pii: 1078-0432.CCR-21-0749.
    PubMed     Abstract available


  79. PRIVE BM, Peters SMB, Muselaers CHJ, van Oort IM, et al
    Lutetium-177-PSMA-617 in low-volume hormone sensitive metastatic prostate cancer, a prospective pilot study.
    Clin Cancer Res. 2021 Apr 21. pii: 1078-0432.CCR-20-4298.
    PubMed     Abstract available


  80. MCKAY RR, Kwak L, Crowdis J, Sperger JM, et al
    Phase 2 multicenter study of enzalutamide in metastatic castration resistant prostate cancer to identify mechanisms driving resistance.
    Clin Cancer Res. 2021 Apr 13. pii: 1078-0432.CCR-20-4616.
    PubMed     Abstract available


    March 2021
  81. WARNER E, Herberts C, Fu S, Yip S, et al
    BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.
    Clin Cancer Res. 2021;27:1650-1662.
    PubMed     Abstract available


  82. CHAKRABORTY G, Patail NK, Hirani R, Nandakumar S, et al
    Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in BRCA2-altered Prostate Tumors.
    Clin Cancer Res. 2021;27:1792-1806.
    PubMed     Abstract available


  83. LIN L, Kane N, Kobayashi N, Kono EA, et al
    High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors.
    Clin Cancer Res. 2021;27:1505-1515.
    PubMed     Abstract available


    January 2021
  84. RESCIGNO P, Gurel B, Pereira R, Crespo M, et al
    Characterizing CDK12-Mutated Prostate Cancers.
    Clin Cancer Res. 2021;27:566-574.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.